PROF 8-K
Profound Medical Corp. (PROF)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________
FORM
_________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
_______________________________
(Exact name of registrant as specified in its charter)
_______________________________
| Not Applicable | ||
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
(Address of Principal Executive Offices) (Zip Code)
Registrant's Telephone Number, Including Area Code:
(Former name or former address, if changed since last report)
_______________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Appointment of Interim Chief Financial Officer
On August 14, 2026, Profound Medical Corp. (the “Company” or “Profound Medical”) announced that Matthew Sobczyk has been appointed by the Board of Directors of the Company (the “Board”) to serve as the Interim Chief Financial Officer of the Company, effective as of the same date (the “Appointment Date”).
Matthew Sobczyk, CPA, CA, age 42, has served in progressively senior financial leadership roles at the Company since May 2017. From March 2023 to August 2026, Mr. Sobczyk served as Corporate Controller of the Company. Prior to that role, he served as Assistant Corporate Controller of the Company from March 2021 to March 2023, and as Manager, Accounting & Reporting of the Company from May 2017 to March 2021. Prior to joining Profound Medical, Mr. Sobczyk spent over a decade in public accounting, audit, and advisory roles with Ernst & Young LLP and MNP LLP. Mr. Sobczyk holds a Bachelor of Arts (Honours Business Administration) from the Richard Ivey School of Business at Western University and earned his Chartered Professional Accountant, Chartered Accountant (CPA, CA) designation in Ontario.
The selection of Mr. Sobczyk to serve as the Company’s Interim Chief Financial Officer was not pursuant to any arrangement or understanding between Mr. Sobczyk and any other person. There are no family relationships between Mr. Sobczyk and any director or executive officer of the Company, and there are no transactions between Mr. Sobczyk and the Company that would be required to be reported under Item 404(a) of Regulation S-K.
In connection with his appointment as Interim Chief Financial Officer, Mr. Sobczyk will receive an annual base salary of CAD 300,414.58. Mr. Sobczyk is eligible to receive an annual discretionary bonus with a target of 15% of his base salary.
Separation Agreement and Contractor Services Agreement
On August 14, 2026, Rashed Dewan resigned from his position as Chief Financial Officer of the Company, effective the same day (the “Separation Date”). In connection with Mr. Dewan’s resignation, the Company and Mr. Dewan entered into a Mutual Separation Agreement, dated August 14, 2026 (the “Separation Agreement”), which provides, among other things, that (i) the Company will pay Mr. Dewan a cash severance payment of $375,000; (ii) for 15 months following the Separation Date, the Company will pay employer contributions to maintain Mr. Dewan’s employee benefits, subject to the terms, conditions and eligibility requirements of the applicable benefit plans and policies; (iii) Mr. Dewan’s vested stock options outstanding as of the Separation Date that were granted under the Company’s Second Amended and Restated Share Option Plan will remain exercisable until the earlier of the last day of the twelve month period immediately following the Separation Date and the stock options’ applicable expiry date; and (iv) the Company will reimburse Mr. Dewan for up to CAD 5,000 in reasonable legal fees incurred in connection with his review of the Separation Agreement. The Separation Agreement also includes a release and waiver by Mr. Dewan and other customary provisions.
In addition, the Company and Mr. Dewan entered into a Contractor Services Agreement, dated August 14, 2026 (the “Contractor Services Agreement”), pursuant to which Mr. Dewan will provide transition and advisory services to the Company as an independent contractor for the period commencing August 17, 2026 through November 25, 2026. Under the Contractor Services Agreement, Mr. Dewan will receive (i) an hourly consulting fee of CAD 200 per hour of hours worked and (ii) continued vesting of 20,000 restricted share units held by Mr. Dewan.
The foregoing description of the Separation Agreement and Contractor Services Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Separation Agreement and the Contractor Services Agreement, copies of which will be filed as exhibits to the Company’s Quarterly Report on Form 10-Q.
On August 14, 2026, the Company issued a press release announcing the appointment of Mr. Sobczyk as Interim Chief Financial Officer of the Company, as described in Item 5.02 above. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or the Exchange Act, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, or the Securities Act. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing with the U.S. Securities Exchange Commission, or the SEC, made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
(d) Exhibits.
| Exhibit No. | Description | |
| 99.1 | Press Release dated, August 14, 2026 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| PROFOUND MEDICAL CORP. | ||
| Date: August 17, 2026 | By: | /s/ Arun Menawat |
| Arun Menawat | ||
| Chief Executive Officer and Chairman | ||
EXHIBIT 99.1
Profound Medical Announces Management Change
TORONTO, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, today announced the promotion of Matthew Sobczyk from Corporate Controller to Interim Chief Financial Officer, effective immediately. Mr. Sobczyk, who first joined Profound in 2020, succeeds Rashed Dewan, who has stepped down as the Company’s Chief Financial Officer.
“I would like to thank Rashed for his years of service and the contributions he has made to the Company, and I am pleased that he will be staying on a short-term consulting contract to help ensure a smooth transition,” said Profound’s CEO and Chairman, Arun Menawat. “At the same time, given Matthew’s deep knowledge of Profound, combined with his financial expertise and experience, we are confident that he is the right leader to maintain continuity and operational discipline while we continue to execute our growth strategy and drive adoption of our award-winning TULSA technology.”
About Profound Medical Corp.
Profound is a commercial-stage medical device company and an innovator in interventional MRI (iMRI) procedures. The company’s flagship platform, TULSA-PRO®, enables MRI-guided, incision-free prostate ablation. Physicians use the TULSA Procedure™ to see, ablate, and confirm therapy in real time, supporting personalized treatment strategies across the continuum of prostate care—from whole-gland to subtotal, hemi, multifocal, and focal treatment. This approach enables individualized care using prostate tissue ablation, while minimizing the potential of the side effects that are typically associated with surgery or radiation, such as urinary incontinence and/or erectile dysfunction.
Profound also commercializes Sonalleve®, an MRI-guided therapy that provides a non-surgical treatment option for pain palliation of bone metastases, desmoid tumors, and osteoid osteoma, as well as for common gynecologic conditions including uterine fibroids and adenomyosis. Sonalleve delivers targeted therapy with no incisions, no blood loss during the procedure, no overnight hospital stay, and faster recovery — and, in gynecologic applications, enables uterine-sparing treatment that may help preserve fertility. Profound is also exploring additional clinical applications for Sonalleve, including non-invasive ablation of abdominal cancers and hyperthermia-based cancer therapies.
Profound Medical’s technologies are approved across major global markets. TULSA-PRO is cleared by the FDA in the United States for transurethral ultrasound ablation (TULSA) of prostate tissue. In addition, TULSA-PRO is cleared for use in various jurisdictions including Europe, Canada, Saudi Arabia, India, Australia/New Zealand, and the UAE. Sonalleve is approved by the FDA as HDE in the United States for the treatment of osteoid osteomas in the extremities. Sonalleve is also cleared or approved in the Europe, Canada, China, and Saudi Arabia.
Through real-time MRI guidance and data-driven innovation, Profound is advancing the future of MRI-guided therapy — expanding access to precise, personalized, and incision-free treatment options worldwide.
Forward-Looking Statements
This release includes forward-looking statements regarding Profound and its business which may include, but is not limited to, the expectations regarding the efficacy of Profound’s technologies for disease conditions requiring MR-Guided ablation procedures for prostate, uterine fibroids, adenomyosis, palliative pain treatment, desmoid tumors, and osteoid osteoma; Profound’s expectations for future revenues/financial results; and the success of Profound’s commercialization strategy and activities for TULSA-PRO® and Sonalleve®. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such statements are based on the current expectations of the management of Profound. The forward-looking events and circumstances discussed in this release, may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks regarding the medical device industry, regulatory approvals, reimbursement, economic factors, the equity markets generally and risks associated with growth and competition. Although Profound has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Other factors and risks that may cause actual results to differ materially from those set out in the forward-looking statements are described in Profound's Annual Report on Form 10-K and other filings made with U.S. and Canadian securities regulators, available at www.sedarplus.com and www.sec.gov. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Profound undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, other than as required by law.
For further information, please contact:
Stephen Kilmer
Investor Relations
[email protected]
T: 647.872.4849